FDA Allows Marketing of First Interoperable Continuous Glucose Monitoring System
FDA announced that it is allowing Dexcom to market its G6 integrated continuous glucose monitoring system (iCGM). It is the first fully interoperable iCGM and can be used to determine the blood glucose levels in children ages two and older and adults with diabetes.
“This is the first type of continuous glucose monitoring system permitted by the agency to be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management,” FDA stated in a news release. “Today’s authorization also classifies this new type of device in class II and subjects it to certain criteria called special controls. This enables developers of future iCGM systems to bring their products to market in the least burdensome manner possible.”
The device is a quarter-sized patch that is applied to the abdomen. A sensor continuously measures glucose in body fluid and transmits the real-time readings every five minutes. If the patient’s sugar enters a dangerous zone, an alarm is triggered. The patch, which should be replaced every 10 days, can also be integrated with an automated insulin dosing system.
Find the fake news: This article is part of the MedTech Intelligence April Fool’s edition. To find out which stories are fake and which are real, log onto our site on Monday afternoon (April 2) and click on each story for the update. You can also sound off in the comments section.
Think this is the fake news? Wrong! Here’s our April Fool’s story.
Related Articles
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
-
The updated guidance document clarifies what constitutes a statement of the basis for the deficiency and includes examples of well-constructed deficiencies and industry responses to facilitate a more efficient review process.
